Contemporary national trends in prostate cancer risk profile at diagnosis

Uro-Oncology

Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

J Urol.

Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW

doi: 10.1016/j.juro.2018.07.065.

Uro-Oncology

Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities

Prostate.

Dee EC, Nezolosky MD, Chipidza FE, Arega MA, Butler SS, Sha ST, Mahal BA, Nguyen PL, Yang DD, Muralidhar V

doi: 10.1002/pros.24041.

Uro-Oncology

Association between metformin medication, genetic variation and prostate cancer risk

Prostate Cancer Prostatic Dis.

Lee MJ, Jayalath VH, Xu W, Lu L, Freedland SJ, Fleshner NE, Kulkarni GS, Finelli A, van der Kwast TH, Hamilton RJ

doi: 10.1038/s41391-020-0238-y.

Uro-Oncology

Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States

Prostate Cancer Prostatic Dis.

Al Hussein Al Awamlh B, Ballman KV, Ma X, Hu JC, Shoag JE

doi: 10.1038/s41391-020-0252-0.

Uro-Oncology

Risk of dementia following androgen deprivation therapy for treatment of prostate cancer

Prostate Cancer Prostatic Dis.

Krasnova A, Epstein M, Marchese M, Dickerman BA, Cole AP, Lipsitz SR, Nguyen PL, Kibel AS, Choueiri TK, Basaria S, Mucci LA, Sun M, Trinh QD

doi: 10.1038/s41391-019-0189-3.

Uro-Oncology

Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study

Prostate Cancer Prostatic Dis.

Beckmann K, Garmo H, Lindahl B, Holmberg L, Stattin P, Adolfsson J, Cruickshank JK, Van Hemelrijck M

doi: 10.1038/s41391-020-0220-8.

Uro-Oncology

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

BJU Int.

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ

doi: 10.1111/bju.13676.

Uro-Oncology

Active Surveillance for Men with Intermediate Risk Prostate Cancer

J Urol.

Agrawal V, Ma X, Hu JC, Barbieri CE, Nagar H

doi: 10.1097/JU.

Uro-Oncology

Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies

Prostate Cancer Prostatic Dis.

Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Fossati N, Shariat SF, Saad F, Montorsi F, Graefen M, Briganti A, Karakiewicz PI

doi: 10.1038/s41391-019-0183-9.

Related content

Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities

Association between metformin medication, genetic variation and prostate cancer risk

Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States

Risk of dementia following androgen deprivation therapy for treatment of prostate cancer

Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

Active Surveillance for Men with Intermediate Risk Prostate Cancer

Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies